188 related articles for article (PubMed ID: 37218920)
1. The bioinformatics analysis of the clinicopathological and prognostic significances of REG4 mRNA in gynecological cancers.
Zhang CY; Zhang L; Wang ZM; Ren DH; Zheng HC
J Obstet Gynaecol; 2023 Dec; 43(1):2213764. PubMed ID: 37218920
[TBL] [Abstract][Full Text] [Related]
2. A bioinformatics analysis of the clinicopathological and prognostic significance of
Zheng HC; Ren DH; Zhang CY; Chen Y; Zhang L
J Obstet Gynaecol; 2023 Dec; 43(1):2216280. PubMed ID: 37227120
[TBL] [Abstract][Full Text] [Related]
3. Bioinformatics analysis of the clinicopathological and prognostic significance of BAG3 mRNA in gynecological cancers.
Wang ZM; Zhang L; Ren DH; Zhang CY; Zheng HC
J Obstet Gynaecol; 2023 Dec; 43(2):2228899. PubMed ID: 37377218
[TBL] [Abstract][Full Text] [Related]
4. Bioinformatic analysis of the clinicopathological and prognostic significance of oocyte-arresting BTG4 mRNA expression in gynecological cancers.
Zheng HC; Xue H; Zhang CY; Zhang R
J Obstet Gynaecol; 2023 Dec; 43(1):2182672. PubMed ID: 36880525
[TBL] [Abstract][Full Text] [Related]
5. The effects of REG4 expression on chemoresistance of ovarian cancer.
Xiang LW; Xue H; Ha MW; Yu DY; Xiao LJ; Zheng HC
J Obstet Gynaecol; 2022 Oct; 42(7):3149-3157. PubMed ID: 35929918
[TBL] [Abstract][Full Text] [Related]
6. The role of the REG4 gene and its encoding product in ovarian epithelial carcinoma.
Chen S; Gou WF; Zhao S; Niu ZF; Zhao Y; Takano Y; Zheng HC
BMC Cancer; 2015 Jun; 15():471. PubMed ID: 26077911
[TBL] [Abstract][Full Text] [Related]
7. The clinicopathological and prognostic significances of Dkk3 expression in cancers: A bioinformatics analysis.
Chen GY; Zheng HC
Cancer Biomark; 2018; 23(3):323-331. PubMed ID: 29843219
[TBL] [Abstract][Full Text] [Related]
8. The clinicopathological significances and related signal pathways of BTG3 mRNA expression in cancers: A bioinformatics analysis.
Zheng HC; Xue H; Zhang CY; Shi KH; Zhang R
Front Genet; 2022; 13():1006582. PubMed ID: 36186486
[TBL] [Abstract][Full Text] [Related]
9. The roles of
Zheng HC; Xue H; Zhang CY; Shi KH; Zhang R
Front Genet; 2022; 13():1006636. PubMed ID: 36339000
[TBL] [Abstract][Full Text] [Related]
10. The clinicopathological and prognostic significances of CDC73 expression in breast cancer: A pathological and bioinformatics analysis.
E Y; Xue H; Zhang CY; Zhao MZ; Zheng HC
Histol Histopathol; 2023 Apr; 38(4):453-465. PubMed ID: 36255176
[TBL] [Abstract][Full Text] [Related]
11. Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients.
Obermayr E; Sanchez-Cabo F; Tea MK; Singer CF; Krainer M; Fischer MB; Sehouli J; Reinthaller A; Horvat R; Heinze G; Tong D; Zeillinger R
BMC Cancer; 2010 Dec; 10():666. PubMed ID: 21129172
[TBL] [Abstract][Full Text] [Related]
12. [Clinical analysis of 23 cases with simultaneous double primary gynecological malignant tumors].
He Y; Wang Y; Ji C; Liu Y; Wu YM
Zhonghua Fu Chan Ke Za Zhi; 2022 May; 57(5):352-360. PubMed ID: 35658326
[No Abstract] [Full Text] [Related]
13. Prognostic and diagnostic value of REG4 serum and tissue expression in pancreatic ductal adenocarcinoma.
Saukkonen K; Hagström J; Mustonen H; Lehtinen L; Carpen O; Andersson LC; Seppänen H; Haglund C
Tumour Biol; 2018 Mar; 40(3):1010428318761494. PubMed ID: 29542402
[TBL] [Abstract][Full Text] [Related]
14. Regenerating gene 4 promotes chemoresistance of colorectal cancer by affecting lipid droplet synthesis and assembly.
Zhang CY; Zhang R; Zhang L; Wang ZM; Sun HZ; Cui ZG; Zheng HC
World J Gastroenterol; 2023 Sep; 29(35):5104-5124. PubMed ID: 37744296
[TBL] [Abstract][Full Text] [Related]
15. REG4 is an indicator for KRAS mutant lung adenocarcinoma with TTF-1 low expression.
Sun S; Hu Z; Huang S; Ye X; Wang J; Chang J; Wu X; Wang Q; Zhang L; Hu X; Yu H
J Cancer Res Clin Oncol; 2019 Sep; 145(9):2273-2283. PubMed ID: 31428934
[TBL] [Abstract][Full Text] [Related]
16. Expression of neurotensin receptor 1 in endometrial adenocarcinoma is correlated with histological grade and clinical outcome.
Agopiantz M; Forgez P; Casse JM; Lacomme S; Charra-Brunaud C; Clerc-Urmès I; Morel O; Bonnet C; Guéant JL; Vignaud JM; Gompel A; Gauchotte G
Virchows Arch; 2017 Oct; 471(4):521-530. PubMed ID: 28836043
[TBL] [Abstract][Full Text] [Related]
17. High expression of S100A2 predicts poor prognosis in patients with endometrial carcinoma.
Zhang Q; Xia T; Qi C; Du J; Ye C
BMC Cancer; 2022 Jan; 22(1):77. PubMed ID: 35042454
[TBL] [Abstract][Full Text] [Related]
18. The clinicopathological and prognostic significances of
Zheng HC; Gong BC; Zhao S
Oncotarget; 2017 Nov; 8(56):95270-95279. PubMed ID: 29221126
[TBL] [Abstract][Full Text] [Related]
19. PSMD8 can serve as potential biomarker and therapeutic target of the PSMD family in ovarian cancer: based on bioinformatics analysis and in vitro validation.
Li X; Li X; Hu Y; Liu O; Wang Y; Li S; Yang Q; Lin B
BMC Cancer; 2023 Jun; 23(1):573. PubMed ID: 37349676
[TBL] [Abstract][Full Text] [Related]
20. Genomic and protein expression analysis reveals flap endonuclease 1 (FEN1) as a key biomarker in breast and ovarian cancer.
Abdel-Fatah TM; Russell R; Albarakati N; Maloney DJ; Dorjsuren D; Rueda OM; Moseley P; Mohan V; Sun H; Abbotts R; Mukherjee A; Agarwal D; Illuzzi JL; Jadhav A; Simeonov A; Ball G; Chan S; Caldas C; Ellis IO; Wilson DM; Madhusudan S
Mol Oncol; 2014 Oct; 8(7):1326-38. PubMed ID: 24880630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
